A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blin... (NCT06709014)

Buntanetap for Early Alzheimer's Disease (NCT06709014)

Overview

Buntanetap mesylate (formerly ANVS401/PD-01) is an oral small molecule drug being developed for the treatment of Alzheimer's disease and Parkinson's disease. This Phase 3 clinical trial (NCT06709014) is evaluating the safety and efficacy of Buntanetap in participants with early Alzheimer's disease["@novel2024"].

The trial is sponsored by Annovis Bio Inc. and represents a significant advancement in developing disease-modifying therapies for neurodegenerative conditions. Buntanetap targets multiple pathological pathways implicated in Alzheimer's disease pathogenesis, including amyloid processing, tau phosphorylation, neuroinflammation, and synaptic dysfunction["@mechanismdriven2024"].

Buntanetap for Early Alzheimer's Disease (NCT06709014)

Overview

Buntanetap mesylate (formerly ANVS401/PD-01) is an oral small molecule drug being developed for the treatment of Alzheimer's disease and Parkinson's disease. This Phase 3 clinical trial (NCT06709014) is evaluating the safety and efficacy of Buntanetap in participants with early Alzheimer's disease["@novel2024"].

The trial is sponsored by Annovis Bio Inc. and represents a significant advancement in developing disease-modifying therapies for neurodegenerative conditions. Buntanetap targets multiple pathological pathways implicated in Alzheimer's disease pathogenesis, including amyloid processing, tau phosphorylation, neuroinflammation, and synaptic dysfunction["@mechanismdriven2024"].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06709014 |
| Phase | Phase 3 |
| Status | RECRUITING |
| Sponsor | Annovis Bio Inc. |
| Enrollment | 760 participants (estimated) |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | February 4, 2025 |
| Completion Date | June 1, 2028 |
| Last Updated | January 30, 2026 |

Conditions Studied

• Early Alzheimer's Disease - Participants with mild cognitive impairment or mild dementia due to AD

Therapeutic Target: Buntanetap Mechanism

Multi-Target Approach

Buntanetap represents a novel approach to Alzheimer's disease therapy by targeting multiple pathological mechanisms simultaneously[@buntanetapmech]:

Molecular Target

Buntanetap acts as a small molecule inhibitor that:

• Binds to amyloid precursor protein (APP) and alpha-synuclein
• Prevents conformational changes that lead to protein aggregation
• Reduces toxic oligomer formation
• Enhances autophagy for clearance of protein aggregates

Scientific Background

Disease Context

Alzheimer's disease (AD) is the most common cause of dementia, affecting approximately 6.5 million Americans alone[@alzheimers2023]. The disease is characterized by:

• Progressive cognitive decline
• Memory loss, particularly for recent events
• Functional impairment affecting daily activities
• Behavioral and psychological symptoms

• Amyloid plaques: Extracellular deposits of amyloid-beta peptide
• Neurofibrillary tangles: Intracellular aggregates of hyperphosphorylated tau
• Synaptic loss: Reduction in synaptic connections
• Neuronal death: Progressive loss of neurons in vulnerable brain regions

Amyloid Cascade Hypothesis

The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis[@amyloid2023]. It proposes that:

However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches that address multiple pathological features simultaneously.

Limitations of Current Therapies

Current FDA-approved treatments for AD include:

• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine)
• Memantine (NMDA receptor antagonist)
• Aducanumab and lecanemab (anti-amyloid antibodies)

Study Design

This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial[@clinical2023]. Phase 3 trials represent the final stage of clinical evaluation before potential regulatory approval and are designed to demonstrate therapeutic efficacy in large patient populations.

Key Design Features

• Randomization: Participants are randomly assigned to treatment or placebo groups (1:1 ratio)
• Double-blind: Neither participants nor investigators know the treatment assignment
• Multi-center: The trial is conducted at multiple sites to ensure diverse patient representation
• Controlled design: Comparison against placebo provides clear evidence of treatment effect

Treatment Arms

| Arm | Description | Duration |
|-----|-------------|----------|
| Buntanetap Low Dose | Oral administration | 6 months / 18 months |
| Buntanetap High Dose | Oral administration | 6 months / 18 months |
| Placebo | Matching oral tablet | 6 months / 18 months |

Outcome Measures

Primary Endpoints

Secondary Endpoints

• Clinical Dementia Rating (CDR) Sum of Boxes
• Mini-Mental State Examination (MMSE)
• Neuropsychiatric Inventory (NPI)
• CSF biomarkers (amyloid-beta, tau, neurofilament light chain)
• Safety and tolerability assessments

Clinical Significance

This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease[@future2024]. The outcomes of this study may:

Why Buntanetap for Alzheimer's?

While originally developed for Parkinson's disease, Buntanetap's mechanism is highly relevant to AD:

• Neuroinflammation reduction: Chronic neuroinflammation drives AD progression; Buntanetap reduces inflammatory markers[@neuroinflammation2024]
• TDP-43 pathology: Increasingly recognized in AD; Buntanetap may address this co-pathology[@tdp432023]
• Synaptic preservation: Protecting synapses is crucial for maintaining cognitive function[@synapse2024]
• Metal homeostasis: Dysregulation of brain metals contributes to neurodegeneration; Buntanetap affects metal handling[@metals2024]

Participating Sites

The trial is being conducted at multiple centers worldwide, including:

• Chandler, Arizona, United States
• Phoenix, Arizona, United States
• Scottsdale, Arizona, United States
• Anaheim, California, United States
• Canoga Park, California, United States
• Los Angeles, California, United States
• San Diego, California, United States
• San Francisco, California, United States
• Denver, Colorado, United States
• Miami, Florida, United States

Related Resources

• [Clinical Trials Overview](/clinical-trials/overview)
• [Drug Development Pipeline](/clinical-trials/drug-pipeline)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Buntanetap Therapeutic](/therapeutics/buntanetap)
• [Amyloid Beta](/proteins/amyloid-beta)
• [Tau Protein](/proteins/tau)
• [Alpha-Synuclein](/proteins/alpha-synuclein)

External Links

• [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT06709014)
• [Annovis Bio Inc.](https://www.annovisbio.com)
• [PubMed Search: Buntanetap Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/?term=buntanetap+Alzheimer)

References